Literature DB >> 1732370

Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination.

D T Kawanishi1, C L Reid, E C Morrison, S H Rahimtoola.   

Abstract

Seventy-four patients with chronic stable mild angina, mild coronary artery disease (83% had one- or two-vessel disease) and normal left ventricular function were studied to measure the response of treadmill exercise performance and painful and silent ischemia in the ambulatory setting to randomly assigned treatment with nifedipine or propranolol and their combination; titration to maximal tolerated dosages was performed in double-blind manner. At 3 months both nifedipine and propranolol reduced the weekly angina rate (p less than 0.05); during treadmill exercise testing, increases (p less than 0.05) were noted in time to angina and total exercise time and decreases in maximal ST depression at the end of exercise. There were no differences between the responses to nifedipine and propranolol and no significant additional changes were seen after another 3 months of therapy. The combination of nifedipine and propranolol reduced the number of patients with angina on exercise treadmill testing from 64% to 38% (p less than 0.05). During ambulatory electrocardiographic monitoring before treatment, there were 1.4 +/- 2.4 (mean +/- SD) episodes/24 h of painful ischemia and a very low silent ischemia frequency: mean 1.1 +/- 2.7 episodes/24 h, mean duration 16 +/- 25 min/24 h. Treatment with propranolol and nifedipine resulted in reduction of episodes and duration of painful and painless ischemia; approximately 77% of patients were free of all ischemic episodes. It is concluded that patients with chronic stable mild angina have a low incidence of silent ischemia. Nifedipine or propranolol alone, titrated to individualized maximally tolerated dosages, are equally effective in long-term control of painful and painless ischemia, anginal episodes and exercise-induced ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732370     DOI: 10.1016/0735-1097(92)90499-d

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Effective management of stable angina.

Authors:  M Petticrew; M Sculpher; J Kelland; R Elliott; D Holdright; M Buxton
Journal:  Qual Health Care       Date:  1998-06

Review 2.  Experimental and early investigational drugs for angina pectoris.

Authors:  Islam Y Elgendy; David E Winchester; Carl J Pepine
Journal:  Expert Opin Investig Drugs       Date:  2016-11-14       Impact factor: 6.206

3.  Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).

Authors:  J A Van Der Vring; M C Daniëls; N J Holwerda; P J Withagen; A Schelling; T J Cleophas; M G Hendriks
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

Review 4.  Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease.

Authors:  Jose B Cruz Rodriguez; Haider Alkhateeb
Journal:  Curr Cardiol Rep       Date:  2020-01-29       Impact factor: 2.931

Review 5.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

Review 6.  Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.

Authors:  Sanjay Kumar; Roger J C Hall
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  Management of Angina Post Percutaneous Coronary Intervention.

Authors:  Jose B Cruz Rodriguez; Subrata Kar
Journal:  Curr Cardiol Rep       Date:  2020-01-21       Impact factor: 2.931

8.  β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial.

Authors:  Harmen G Booij; Kevin Damman; J Wayne Warnica; Jean L Rouleau; Wiek H van Gilst; B Daan Westenbrink
Journal:  Cardiovasc Drugs Ther       Date:  2015-06       Impact factor: 3.727

9.  Association between perioperative β-blocker use and clinical outcome of non-cardiac surgery in coronary revascularized patients without severe ventricular dysfunction or heart failure.

Authors:  Jungchan Park; Jeayoun Kim; Ji Hye Kwon; Soo Jung Park; Jeong Jin Min; Sangmin Maria Lee; Hyeon-Cheol Gwon; Young Tak Lee; Myungsoo Park; Seung Hwa Lee
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.